Association of short-term cognitive decline and MCI-to-AD dementia conversion with CSF, MRI, amyloid- and (18)F-FDG-PET imaging

Disease-modifying treatment trials are increasingly advanced to the prodromal or preclinical phase of Alzheimer's disease (AD), and inclusion criteria are based on biomarkers rather than clinical symptoms. Therefore, it is of great interest to determine which biomarkers should be combined to ac...

Descripción completa

Detalles Bibliográficos
Autores principales: Ottoy, Julie, Niemantsverdriet, Ellis, Verhaeghe, Jeroen, De Roeck, Ellen, Struyfs, Hanne, Somers, Charisse, wyffels, Leonie, Ceyssens, Sarah, Van Mossevelde, Sara, Van den Bossche, Tobi, Van Broeckhoven, Christine, Ribbens, Annemie, Bjerke, Maria, Stroobants, Sigrid, Engelborghs, Sebastiaan, Staelens, Steven
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2019
Materias:
Regular Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6444289/
https://www.ncbi.nlm.nih.gov/pubmed/30927601
http://dx.doi.org/10.1016/j.nicl.2019.101771

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6444289/
https://www.ncbi.nlm.nih.gov/pubmed/30927601
http://dx.doi.org/10.1016/j.nicl.2019.101771

Ejemplares similares